Open AccessPhosphoinositide Conversion Inactivates R‐RAS and Drives Metastases in Breast Cancer
Author(s) -
Li Huayi,
Prever Lorenzo,
Hsu Myriam Y.,
Lo WenTing,
Margaria Jean Piero,
De Santis Maria Chiara,
Zanini Cristina,
Forni Marco,
Novelli Francesco,
Pece Salvatore,
Di Fiore Pier Paolo,
Porporato Paolo Ettore,
Martini Miriam,
Belabed Hassane,
Nazare Marc,
Haucke Volker,
Gulluni Federico,
Hirsch Emilio
Publication year - 2022
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.202103249
Subject(s) - breast cancer , focal adhesion , medicine , cancer , metastasis , cancer research , metastatic breast cancer , oncology , cell , biology , genetics
Breast cancer is the most prevalent cancer and a major cause of death in women worldwide. Although early diagnosis and therapeutic intervention significantly improve patient survival rate, metastasis still accounts for most deaths. Here it is reported that, in a cohort of more than 2000 patients with breast cancer, overexpression of PI3KC2 α occurs in 52% of cases and correlates with high tumor grade as well as increased probability of distant metastatic events, irrespective of the subtype. Mechanistically, it is demonstrated that PI3KC2 α synthetizes a pool of PI(3,4)P2 at focal adhesions that lowers their stability and directs breast cancer cell migration, invasion, and metastasis. PI(3,4)P2 locally produced by PI3KC2 α at focal adhesions recruits the Ras GTPase activating protein 3 (RASA3), which inactivates R‐RAS, leading to increased focal adhesion turnover, migration, and invasion both in vitro and in vivo. Proof‐of‐concept is eventually provided that inhibiting PI3KC2 α or lowering RASA3 activity at focal adhesions significantly reduces the metastatic burden in PI3KC2 α ‐overexpressing breast cancer, thereby suggesting a novel strategy for anti‐breast cancer therapy.